-
1.发明授权Method for inhibiting activation of the human A3 adenosine receptor to treat asthma 失效抑制人A3腺苷受体活化以治疗哮喘的方法
公开(公告)号：US5780481A
公开(公告)日：1998-07-14
申请号：US694061
申请日：1996-08-08
IPC分类号： A61K31/4375 , A61K31/44 , A61K31/34 , A61K31/41
CPC分类号： A61K31/4375
摘要： The invention is a method for inhibiting activation of the human A3 adenosine receptor with adenosine, by treating the receptor a compound of the formula ##STR1## to treat asthma.
摘要翻译： 本发明是用腺苷抑制人A3腺苷受体活化的方法，通过用受体将式（Ⅰ）化合物治疗哮喘来治疗。
-
公开(公告)号：US5599671A
公开(公告)日：1997-02-04
申请号：US349696
申请日：1994-12-05
IPC分类号： C07K14/705 , C12N15/12 , C12N5/10
CPC分类号： C07K14/705
摘要： The invention concerns recombinant human adenosine receptors A1, A2a, A2b and A3 which have been prepared by cDNA cloning and polymerase chain reaction techniques. The invention also concerns expression systems for these receptors and an assay using the expression systems. The recombinant adenosine receptors comprising the invention can be utilized in an assay to identify and evaluate entities that bind to or enhance binding to adenosine receptors.
摘要翻译： 本发明涉及通过cDNA克隆和聚合酶链反应技术制备的重组人腺苷受体A1，A2a，A2b和A3。 本发明还涉及这些受体的表达系统和使用表达系统的测定法。 包含本发明的重组腺苷受体可用于测定以鉴定和评估与腺苷受体结合或增强结合的实体。
-
3.发明授权Inhibition of eosinophil activation through A3 adenosine receptor antagonism 失效通过A3腺苷受体拮抗作用抑制嗜酸性粒细胞活化
公开(公告)号：US5646156A
公开(公告)日：1997-07-08
申请号：US233009
申请日：1994-04-25
IPC分类号： A61K31/00 , A61K31/52 , A61K31/675 , A61K38/00 , C07K14/705
CPC分类号： A61K31/675 , A61K31/00 , A61K31/52 , C07K14/705 , A61K38/00 , Y10S514/826 , Y10S514/861 , Y10S514/863 , Y10S514/87 , Y10S514/886
摘要： The invention concerns the identification on eosinophils of the A3 adenosine receptor subtype and the blockade of said receptor in order to achieve inhibition of eosinophil activation and degranulation.
摘要翻译： 本发明涉及A3腺苷受体亚型的嗜酸性粒细胞的鉴定和所述受体的封锁，以便实现嗜酸性粒细胞活化和脱粒的抑制。
-
公开(公告)号：US6166181A
公开(公告)日：2000-12-26
申请号：US80704
申请日：1998-05-18
IPC分类号： C07K14/705 , C12N15/12
CPC分类号： C07K14/705
摘要： The invention concerns recombinant human adenosine receptors A1, A2a, A2b and A3 which have been prepared by cDNA cloning and polymerase chain reaction techniques. The invention also concerns expression systems for these receptors and an assay using the expression systems. The recombinant adenosine receptors comprising the invention can be utililized in an assay to identify and evaluate entities that bind to or enhance binding to adenosine receptors.
摘要翻译： 本发明涉及通过cDNA克隆和聚合酶链反应技术制备的重组人腺苷受体A1，A2a，A2b和A3。 本发明还涉及这些受体的表达系统和使用表达系统的测定法。 包含本发明的重组腺苷受体可用于测定中以鉴定和评估与腺苷受体结合或增强结合的实体。
-
公开(公告)号：US5817760A
公开(公告)日：1998-10-06
申请号：US560231
申请日：1996-03-27
IPC分类号： C07K14/705 , C12N15/12
CPC分类号： C07K14/705
摘要： The invention concerns recombinant human adenosine receptors A1, A2a, A2b and A3 which have been prepared by cDNA cloning and polymerase chain reaction techniques. The invention also concerns expression systems for these receptors and an assay using the expression systems. The recombinant adenosine receptors comprising the invention can be utililized in an assay to identify and evaluate entities that bind to or enhance binding to adenosine receptors.
摘要翻译： 本发明涉及通过cDNA克隆和聚合酶链反应技术制备的重组人腺苷受体A1，A2a，A2b和A3。 本发明还涉及这些受体的表达系统和使用表达系统的测定法。 包含本发明的重组腺苷受体可用于测定中以鉴定和评估与腺苷受体结合或增强结合的实体。
-
-
-
-
搜索结果
5 条记录 (耗时 0.019 秒)
